2120397-85-3
Chemical Structure
d-T101 peptide
- CAS No.: 2120397-85-3
- Formula:C96H129N21O20
- Molecular Weight:1897.18
SMILES: NCCCC[C@H](C(O)=O)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCC(O)=O)NC([C@H](NC([C@@H](CC(C)C)NC([C@@H]([C@@H](O)C)NC([C@@H](CO)NC([C@@H]1N(CCC1)C([C@@H](CC(C)C)NC([C@H](NC([C@H](NC([C@@H]([C@@H](O)C)NC([C@H](NC([C@H](N)CC2=CNC3=CC=CC=C23)=O)CC4=CNC5=CC=CC=C45)=O)=O)CC6=CC=CC=C6)=O)CC7=CC=CC=C7)=O)=O)=O)=O)=O)=O)CC8=CNC9=CC=CC=C89)=O)=O)=O
Biological Activity: d-T101 peptide, a human hormone-peptide, is a T1/ST2 receptor ligand. d-T101 peptide binds to the T1/ST2 receptor and activates caspases 8, 9 and 3 mediated apoptosis, together with activation of JNKinase and p38 MAPKinase. d-T101 peptide also changes Golgi structural with function loss and downregulation of the endoplasmic reticulum (ER) stress repair mechanism. d-T101 peptide has immunostimulatory and anticancer activity, selectively induces apoptosis in proliferating cancer cells and increases IL-2 and IFN-γ expression as well as the recruitment of NK cells and M1 macrophages to the tumor site[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
d-T101 peptide | d-T101 peptide, a human hormone-peptide, is a T1/ST2 receptor ligand. d-T101 peptide binds to the T1/ST2 receptor and activates caspases 8, 9 and 3 mediated apoptosis, together with activation of JNKinase and p38 MAPKinase. d-T101 peptide also changes Golgi structural with function loss and downregulation of the endoplasmic reticulum (ER) stress repair mechanism. d-T101 peptide has immunostimulatory and anticancer activity, selectively induces apoptosis in proliferating cancer cells and increases IL-2 and IFN-γ expression as well as the recruitment of NK cells and M1 macrophages to the tumor site. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Sandler U, et al. NEROFE--a novel human hormone-peptide with anti-cancer activity. J Exp Ther Oncol. 2010;8(4):327-39. [Content Brief]
- [2]. Ohana J, et al. dTCApFs, a derivative of a novel human hormone peptide, induces apoptosis in cancer cells through a mechanism involving loss of Golgi function. Mol Clin Oncol. 2017 Dec;7(6):991-999. [Content Brief]
- [3]. Ohana J, et al. Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin. Oncotarget. 2023 Jul 1;14:688-699. [Content Brief]
Keywords
